Hydroxicloroquine for pre-exposure prophyylaxis for SARS-CoV-2

DOI record: { "DOI": "10.1101/2020.08.31.20185314", "URL": "http://dx.doi.org/10.1101/2020.08.31.20185314", "abstract": "<jats:title>ABSTRACT</jats:title><jats:p>SARS-CoV-2 infection has a high transmission level. At the present time there is not a specific treatment approved but it is known that, in vitro, chloroquine and hydroxychloroquine can inhibit the coronavirus.</jats:p><jats:sec><jats:title>Objective</jats:title><jats:p>verifying if patients with autoimmune diseases that are on treatment with HCQ have less incidence and severity on COVID-19.</jats:p></jats:sec><jats:sec><jats:title>Material and methods</jats:title><jats:p>this is a retrospective cohort study. The exposed cohort was formed by individuals with autoimmune diseases with HCQ treatment. The control cohort was randomly selected using the Health Card database. To deal with confounding variables and evaluate the effect of HCQ on the incidence and severity of SARS-CoV-2 infection, propensity score matching was used. Risk difference and paired percentage difference between exposed and non-exposed groups was estimated.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>919 individuals formed the exposed cohort and 1351 the control cohort. After matching, there were 690 patients on each group. During the time of the study, in the exposed group there were 42 (6.1%) individuals with suspected COVID-19, 12(1.7%) with confirmed COVID-19 and 3(0.4%) were hospitalized. In the control group there were 30(4.3%) individuals with suspected COVID-19, 13(1.9%) with confirmed COVID-19 and 2(0.3%) were hospitalized. The risk difference between each cohort was: 0.017(−0.05-0.04) for suspected COVID-19; -0.014(−0.015-0.012) for confirmed COVID-19 and 0.001(−0.007-0.007) for hospitalized patients. There were not significant differences.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>there is no difference neither on the incidence nor on the severity of COVID-19 between patients with autoimmune diseases with HCQ treatment and patients that do not take HCQ.</jats:p></jats:sec>", "accepted": { "date-parts": [ [ 2020, 9, 15 ] ] }, "author": [ { "affiliation": [], "family": "de la Iglesia", "given": "Jaime López", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0002-3912-0435", "affiliation": [], "authenticated-orcid": false, "family": "Fernández", "given": "Naiara Cubelos", "sequence": "additional" }, { "affiliation": [], "family": "Flores", "given": "Roi Naveiro", "sequence": "additional" }, { "affiliation": [], "family": "Gómez", "given": "Marina Montoro", "sequence": "additional" }, { "affiliation": [], "family": "González de Haro", "given": "Francisco Javier", "sequence": "additional" }, { "affiliation": [], "family": "González", "given": "María Ajenjo", "sequence": "additional" }, { "affiliation": [], "family": "Vicente", "given": "Estefanía Tobal", "sequence": "additional" }, { "affiliation": [], "family": "Gil de Gómez", "given": "María Lamuedra", "sequence": "additional" }, { "affiliation": [], "family": "Guisado", "given": "María Teresa Nuevo", "sequence": "additional" }, { "affiliation": [], "family": "Gómez", "given": "Isabel Torio", "sequence": "additional" }, { "affiliation": [], "family": "Andrada", "given": "Ana Peñalver", "sequence": "additional" }, { "affiliation": [], "family": "Cao", "given": "Nuria Martínez", "sequence": "additional" }, { "affiliation": [], "family": "Figaredo", "given": "Paula González", "sequence": "additional" }, { "affiliation": [], "family": "García", "given": "Carlos Robles", "sequence": "additional" }, { "affiliation": [], "family": "Machón", "given": "Lidia Anastasia Alvarado", "sequence": "additional" }, { "affiliation": [], "family": "Alcalde", "given": "Ángeles Lafont", "sequence": "additional" }, { "affiliation": [], "family": "Rilo", "given": "José Cesáreo Naveiro", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2020, 9, 2 ] ], "date-time": "2020-09-02T22:00:17Z", "timestamp": 1599084017000 }, "deposited": { "date-parts": [ [ 2022, 11, 16 ] ], "date-time": "2022-11-16T03:39:12Z", "timestamp": 1668569952000 }, "group-title": "Rheumatology", "indexed": { "date-parts": [ [ 2022, 11, 17 ] ], "date-time": "2022-11-17T05:30:15Z", "timestamp": 1668663015589 }, "institution": [ { "name": "medRxiv" } ], "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2020, 9, 2 ] ] }, "link": [ { "URL": "https://syndication.highwire.org/content/doi/10.1101/2020.08.31.20185314", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "246", "original-title": [], "posted": { "date-parts": [ [ 2020, 9, 2 ] ] }, "prefix": "10.1101", "published": { "date-parts": [ [ 2020, 9, 2 ] ] }, "publisher": "Cold Spring Harbor Laboratory", "reference": [ { "DOI": "10.1016/S1473-3099(03)00806-5", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.1" }, { "DOI": "10.1021/jm0601856", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.2" }, { "article-title": "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome main point: hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit", "first-page": "1", "journal-title": "Clin Infect Dis", "key": "2021021307151133000_2020.08.31.20185314v2.3", "volume": "2", "year": "2020" }, { "DOI": "10.1002/cpt.1874", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.4" }, { "DOI": "10.1101/2020.03.22.20040758", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.5", "unstructured": "Zhaowei Chen , Jijia Hu , Zongwei Zhang , Shan Jiang , Shoumeng Han , Dandan Yan , et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. [Preprint]. March 2020. doi: 10.1101/2020.03.22.20040758. Available from: https://pubmed.ncbi.nlm.nih.gov/16640347/" }, { "DOI": "10.1016/j.ijantimicag.2020.105949", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.6" }, { "DOI": "10.1016/j.tmaid.2020.101738", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.7", "unstructured": "Million M , Lagier JC , Gautret P , Colson P , Fournier P , Amrane S . Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France [Preprint]. May 2020. Travel Med Infect Dis. 2020; 101738. https://doi.org.10.1016/j.tmaid.2020.101" }, { "DOI": "10.1136/bmj.m1849", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.8", "unstructured": "Tang W , Cao Z , Han M , Wang Z , Chen J , Sun W . Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ May 2020; 369 doi: https://doi.org/10.1136/bmj.m1849" }, { "DOI": "10.1136/bmj.m1844", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.9", "unstructured": "Mahévas M , Tran VT , Roumier M , Chabrol A , Paule R , Guillaud C . Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020; 369. Doi: https://doi.org/10.1136/bmj.m1844" }, { "DOI": "10.1001/jama.2020.8630", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.10" }, { "DOI": "10.1016/j.ijantimicag.2020.105988", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.11" }, { "DOI": "10.1101/2020.03.22.20040758", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.12" }, { "DOI": "10.1136/annrheumdis-2020-217506", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.13" }, { "key": "2021021307151133000_2020.08.31.20185314v2.14", "unstructured": "James S .Brady Press Briefing Room. Remarks by President Trump, Vice President Pence, and Members of the Coronavirus Task Force in Press Briefing. Available from: https://www.whitehouse.gov/briefings-statements/remarks-president-trump-vice-president-pence-members-coronavirus-task-force-press-briefing-31/" }, { "DOI": "10.1136/annrheumdis-2020-217566", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.15" }, { "DOI": "10.1136/annrheumdis-2020-217690", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.16" }, { "DOI": "10.1093/biomet/70.1.41", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.17" }, { "DOI": "10.18637/jss.v045.i03", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.18", "unstructured": "Buuren, S. V. , & Groothuis-Oudshoorn, K. Mice: Multivariate imputation by chained equations in R. Journal of statistical software 2010, 1-68." }, { "DOI": "10.1016/j.autrev.2020.102575", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.19" }, { "DOI": "10.1177/1536867X0200200403", "article-title": "Estimation of average treatment effects based on propensity scores", "doi-asserted-by": "crossref", "first-page": "358", "journal-title": "The Stata journal", "key": "2021021307151133000_2020.08.31.20185314v2.20", "volume": "2", "year": "2002" }, { "DOI": "10.18637/jss.v045.i03", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.21", "unstructured": "Buuren, S. V. , & Groothuis-Oudshoorn, K. Mice: Multivariate imputation by chained equations in R. Journal of statistical software. 2010. 1-68" }, { "DOI": "10.18637/jss.v042.i07", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.22", "unstructured": "Sekhon, J. S. (2008). Multivariate and propensity score matching software with automated balance optimization: the matching package for R. Journal of Statistical Software. 2011. 42(7). Doi: http://dx.doi.org/10.18637/jss.v042.i07" }, { "DOI": "10.1016/j.recesp.2011.05.009", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.23" }, { "DOI": "10.1056/NEJMoa2007621", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.24" }, { "article-title": "Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study [published online ahead of print, 2020 May 19]", "first-page": "31189", "issue": "20", "journal-title": "Lancet", "key": "2021021307151133000_2020.08.31.20185314v2.25", "volume": "S0140-6736", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30566-3", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.26" }, { "DOI": "10.1101/2020.05.11.20097808", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.27", "unstructured": "Pablos JL , Abasolo-Alcázar L , Álvaro-Gracia JM , Blanco FJ et al. Prevalence of hospital PCR confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis, 2020. Doi: https://doi.org/10.1101/2020.05.11.20097808" }, { "DOI": "10.1136/annrheumdis-2020-217888", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.28", "unstructured": "D’Silva KM , Serling-Boyd N , Wallwork R , et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’ [published online ahead of print, 2020 May 26]. Ann Rheum Dis. 2020;doi: https://doi.org/10.1136/annrheumdis-2020-217888" }, { "DOI": "10.1136/annrheumdis-2020-218713", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.29", "unstructured": "Gianfrancesco M , Hyrich KL , Al-Adely S , et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID 19 Global Rheumatology Alliance physician-reported registry [published online ahead of print, 2020 May 29]. Ann Rheum Dis. 2020." }, { "DOI": "10.1101/2020.06.18.20133645", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.30", "unstructured": "Pablos JL , Galindo M , Carmona L , Retuerto M , Lledó A , Blanco R , González-Gay MA , et al. Clinical Outcomes of Patients with COVID-19 and Chronic Inflammatory and Autoimmune Rheumatic Diseases: A Multicentric Matched-Cohort Study. [Preprintt].2020. doi: https://doi.org/10.1101/2020.06.18.20133645" }, { "DOI": "10.1111/1756-185X.13842", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.31" }, { "DOI": "10.1056/NEJMoa2019014", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.32" }, { "DOI": "10.1056/NEJMoa2016638", "doi-asserted-by": "publisher", "key": "2021021307151133000_2020.08.31.20185314v2.33" }, { "DOI": "10.1101/2020.05.16.20104141", "doi-asserted-by": "crossref", "key": "2021021307151133000_2020.08.31.20185314v2.34", "unstructured": "Macias J , Gonzalez-Moreno P , Sanchez-Garcia E , Morillo-Verdugo R , Dominguez-Quesada C , Pinilla A . Similar incidence of Coronavirus Disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. [Preprint] 2020. Doi: https://doi.org/10.1101/2020.05.16.20104141" } ], "reference-count": 34, "references-count": 34, "relation": {}, "resource": { "primary": { "URL": "http://medrxiv.org/lookup/doi/10.1101/2020.08.31.20185314" } }, "score": 1, "short-title": [], "source": "Crossref", "subtitle": [], "subtype": "preprint", "title": "Hydroxicloroquine for Pre-Exposure Prophylaxis for SARS-COV-2", "type": "posted-content" }